SBIR/STTR Research Award

Topical Eyedrop Therapy for Keratoconus

Award identifier 2136c41555b1545ee6bcf6b18693072f0529989b633eab30ddc94e9b3bd75f31Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,767

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Iveena Delivery Systems, Inc.
Proposal award date
2017-09-30
Contract end date
2018-09-29
UEI
EQ3KNDP93M27
Solicitation number
PA16-302
Topic code
N

Research abstract

Project Summary Keratoconus KCN is a progressive disorder associated with structural changes in corneal collagen organization that leads to corneal thinning and ruptures in Bowman s layer and or Descemet s membrane As the disease progresses it leads to irregular astigmatism progressive myopia and subsequently poor visual acuity Treatment options are surprisingly limited with no oral or topical pharmaceutical therapy Most mild KCN can be corrected with glasses or soft contact lenses but very often patients will need toric or hard contacts as the disease progresses Ultimately in patients will require surgery Our technology is based on a co factor for lysyl oxidase LOX activity and that low LOX activity in the cornea has been linked to the development of keratoconus both genetically and biochemically We provide the evidence in preliminary results of a new topical eye drop effect on human keratoconus corneas in increasing both LOX activity and cornea stiffening We also show the first morphological evidence of induced central corneal flattening in rabbits with optical coherence tomography OCT Based on the current evidence base we outline new proactive pathways for keratoconus management and enabling a non invasive and relatively cost effective treatment for keratoconus We propose a research plan under three specific aims that will a study the safety and tolerability of the eye drops in rabbits in vivo b study the effect of dosing frequency on rabbit corneal shape and biochemical crosslinking in vivo and c to determine whether the eye drops induce biochemical crosslinking on human keratoconic corneas ex vivo Project Narrative Keratoconus is a non inflammatory progressive thinning of the cornea that is usually bilateral and involves the central two thirds of the cornea The thinning of cornea leads to irregular astigmatism progressive myopia and subsequently poor visual acuity iVeena is proposing a new topical drug therapy for keratoconus The proposed project has significance in terms of scientific relevance in elucidating a poorly understood disease condition keratoconus and the potential for advancing ocular therapeutics for other corneal thinning disorders

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

7 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $5,630,748. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.